Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Long-Term Investments (2025)

Maze Therapeutics has reported Long-Term Investments over the past 1 years, most recently at $18.1 million for Q4 2025.

  • Quarterly Long-Term Investments changed N/A to $18.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $18.1 million for FY2025, N/A changed from the prior year.
  • Long-Term Investments was $18.1 million for Q4 2025 at Maze Therapeutics.
  • Over five years, Long-Term Investments peaked at $18.1 million in Q4 2025 and troughed at $18.1 million in Q4 2025.